Home › Funds › SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC › ARWR

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reported holding 830,247 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$67.7M, representing 1.82% of its reported portfolio and ranking #12 among its reported holdings. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed ARWR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)830.25K sh
Reported value held$67.67M
Portfolio Weight1.82%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's ARWR position evolved

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC first disclosed a stake in ARWR in Q4 2025 at 200,000 shares (US$13.3M). The position peaked in Q2 2026 at 830,247 shares, worth US$67.7M. Across 3 filings, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 830,247 shares valued at US$67.7M — an increase of 680,247 shares quarter over quarter.. Notable position changes include a 25% trim in Q1 2026 (shares rose 30% over the following quarter), a 453% increase in Q2 2026 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 200.00K $13.28M New
Q1 2026 150.00K $9.40M Reduce
Q2 2026 830.25K $67.67M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 52 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC held ARWR?

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed ARWR holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's current position in ARWR?

As of Q2 2026, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds 830.25K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $67.67M, representing 1.82% of its reported portfolio and ranking #12.

Has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC been buying or selling ARWR?

In the latest 13F filing (Q2 2026), SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased its position in ARWR. The position peaked in Q2 2026 at 830.25K shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.